Literature DB >> 14584071

K-ras mutation in tamoxifen-related endometrial polyps.

Toru Hachisuga1, Takashi Miyakawa, Hiroshi Tsujioka, Shinji Horiuchi, Makoto Emoto, Tatsuhiko Kawarabayashi.   

Abstract

BACKGROUND: K-ras mutation is thought to occur at an early stage of neoplastic progression in the endometrium. The authors investigated mutations in codon 12 of K-ras in tamoxifen (TAM)-related endometrial polyps.
METHODS: DNA was extracted from 11 frozen endometrial polyps from TAM-treated patients with breast carcinoma. Mutations were detected using the mutant allele-specific amplification method. The results subsequently were analyzed for correlations with immunohistochemical data that were obtained using antibodies against estrogen receptors (ERs; alpha and beta forms), progesterone receptors (PRs; A and B forms), and Ki-67.
RESULTS: Mutations in codon 12 of K-ras were observed in 7 of 11 TAM-related endometrial polyps. Expression levels of ER-alpha and PR-B were high in the glandular epithelium and low in the stroma. PR-A expression was high in both the glandular epithelium and the stroma. In the glandular epithelium, expression of ER-beta appeared to be lower than expression of ER-alpha. The Ki-67 index in the glandular epithelium ranged from 2 to 38, whereas the index ranged from 0 to 4 in the stroma (P < 0.01).
CONCLUSIONS: The incidence of mutations in codon 12 of K-ras in TAM-related endometrial polyps (64%) was greater than the incidence of these same mutations in sporadic endometrial hyperplasias (4.5-23%). High expression levels of ER-alpha, PR-A, and PR-B in the glandular epithelium were observed in all polyps, regardless of K-ras codon 12 mutation status and Ki-67 index. The authors' findings may support the hypothesis that the polyp-carcinoma sequence partly indicates the development of endometrial carcinoma in postmenopausal women who have been treated with TAM. Copyright 2003 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14584071     DOI: 10.1002/cncr.11728

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  10 in total

1.  Peroxidase-mediated dealkylation of tamoxifen, detected by electrospray ionization-mass spectrometry, and activation to form DNA adducts.

Authors:  Nilesh W Gaikwad; William J Bodell
Journal:  Free Radic Biol Med       Date:  2011-10-18       Impact factor: 7.376

2.  [Changes in the endometrium after tamoxifen therapy].

Authors:  D Schmidt
Journal:  Pathologe       Date:  2006-02       Impact factor: 1.011

3.  Alteration of the k-ras gene expression in atypical and nonatypical hyperplastic endometrium.

Authors:  Narges Izadi-Mood; Soheila Sarmadi; Behzad Rostamnasl
Journal:  Iran J Cancer Prev       Date:  2013

4.  Effects of tamoxifen on the endometrium and its mechanism of carcinogenicity.

Authors:  Akira Yasue; Kiyoshi Hasegawa; Yasuhiro Udagawa
Journal:  Hum Cell       Date:  2011-01-22       Impact factor: 4.174

5.  MGMT promoter hypermethylation and K-RAS, PTEN and TP53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases.

Authors:  E Nagy; K B Gajjar; I I Patel; S Taylor; P L Martin-Hirsch; H F Stringfellow; F L Martin; D H Phillips
Journal:  Br J Cancer       Date:  2014-05-22       Impact factor: 7.640

6.  Molecular mechanisms of tamoxifen-associated endometrial cancer (Review).

Authors:  Rong Hu; Leena Hilakivi-Clarke; Robert Clarke
Journal:  Oncol Lett       Date:  2015-02-12       Impact factor: 2.967

7.  Microarray analysis on gene regulation by estrogen, progesterone and tamoxifen in human endometrial stromal cells.

Authors:  Chun-E Ren; Xueqiong Zhu; Jinping Li; Christian Lyle; Sean Dowdy; Karl C Podratz; David Byck; Hai-Bin Chen; Shi-Wen Jiang
Journal:  Int J Mol Sci       Date:  2015-03-13       Impact factor: 5.923

Review 8.  The significance of markers in the diagnosis of endometrial cancer.

Authors:  Monika M Żyła; Jacek R Wilczyński; Marta Kostrzewa; Kinga Księżakowska-Łakoma; Marek Nowak; Grzegorz Stachowiak; Krzysztof Szyłło; Tomasz Stetkiewicz
Journal:  Prz Menopauzalny       Date:  2016-11-15

9.  K-ras mutation in the endometrium of tamoxifen-treated breast cancer patients, with a comparison of tamoxifen and toremifene.

Authors:  T Hachisuga; H Tsujioka; S Horiuchi; T Udou; M Emoto; T Kawarabayashi
Journal:  Br J Cancer       Date:  2005-03-28       Impact factor: 7.640

Review 10.  The Potential Role of Nutraceuticals as an Adjuvant in Breast Cancer Patients to Prevent Hair Loss Induced by Endocrine Therapy.

Authors:  Giorgio Dell'Acqua; Aleksander Richards; M Julie Thornton
Journal:  Nutrients       Date:  2020-11-18       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.